MARK2 and ischemia: Specific PAR1 antagonists, in addition to NMDA receptor blockers in clinical use such as Ketamine would very likely be useful in preventing PAR1 from inducing NMDA receptor-mediated neuronal damage resulting from ischemia or haemorrhage.